Lower dose abiraterone without hormone shots for prostate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a lower dose of abiraterone (a pill that lowers testosterone) without the usual hormone-blocking shots for men with prostate cancer that needs hormone therapy. It is for patients at high risk or with early spread who have not had hormone therapy before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and have prostate cancer that was confirmed by a biopsy.
- You are being treated at Hospital Durand in Argentina or Instituto Oncológico del Oriente Boliviano in Bolivia.
- Your doctor recommends hormonal therapy for high-risk prostate cancer or for cancer that has spread but is still hormone-sensitive.
- You have not had hormone therapy (like Lupron or Zoladex) before.
- You are in good general health, with normal kidney and liver function, normal potassium levels, and controlled blood pressure.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding abiraterone (a hormone therapy pill) and prednisone to standard hormone therapy (ADT) for prostate cancer that has spread to nearby lymph nodes but is too small to see on regular scans. The goal is to see if this combination works better than ADT alone.
This trial tests whether a new version of the drug abiraterone (abiraterone acetate II) works as well as the standard version for men with metastatic castration-resistant prostate cancer (MCRPC) that has progressed. You may qualify if you have already had one type of hormone therapy or chemotherapy and your cancer is spreading.
This trial studies how well abiraterone (a hormone-blocking medicine) plus prednisone (a steroid) works in people with metastatic, hormone-sensitive prostate cancer. It also looks at whether results differ by race/ethnicity and other health factors.
This trial tests a new combination of two study drugs (HRS-1167 and abiraterone with prednisone) for men with prostate cancer that has spread beyond the prostate. The goal is to see if the combination works better than current treatments.
This study is comparing two drugs, abiraterone and darolutamide, to see how well they work for advanced prostate cancer. You might join if your cancer has spread and your doctor agrees these treatments could help.
This trial tests whether some men with high-risk prostate cancer can safely receive less hormone therapy when combined with radiation. It aims to reduce side effects while still effectively treating the cancer.
Hear when a new Prostate Cancer (Diagnosis) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.